The Drug That Ate Your
Business Model
GLP-1 receptor agonists are no longer just a clinical breakthrough—they are a macro-economic force. As 1 in 8 North American adults rewire their neurobiology, industries once built on habitual cravings are seeing their fundamental unit economics dissolve.
GLP-1 receptor agonists represent the most significant disruption to consumer behavior since the industrialization of food, yet most corporate strategies remain anchored in 20th-century assumptions. The question is no longer if your category is exposed, but whether you are attempting to defend a status quo that has already been invalidated by the user’s brain.
This decision brief examines this transition through the lenses of neurochemical disruption, hidden clinical liabilities, and the unclaimed platform opportunity to show exactly when leaders should defend, pivot, or build new models entirely.
Key Findings
1.
Disruption starts in the brain, not the gut. GLP-1 drugs rewire the reward-seeking dopamine pathways. This is not about hunger. It is about the erosion of cravings for food, alcohol, and nicotine alike. Any business model built on habitual repurchase is now vulnerable.
2.
Satiety is solved. Micronutrient density is not. The drug already suppresses appetite. Products offering more fullness are redundant. The real opportunity lies in micronutrient integrity, calcium, vitamin D, and magnesium, to bridge the inevitable intake gap.
3.
The bone loss risk is documented. The product response is not. Significant bone mineral density loss is surfacing in users without exercise protocols. These clinical risks are silent, accumulating without symptoms, and represent a future liability for any company failing to provide whole-person care.
4.
The revenue headwind is neurochemical, not seasonal. This is not a temporary diet trend. The 41% reduction in alcohol consumption and the decline in tobacco use are neurochemical shifts that hold as long as therapy continues. The pressure on affected revenue models is structural.
5.
A 58-point support gap remains unclaimed. 75% of users want behavioral support. Only 17% receive it. This misalignment between demand and provision is the primary entry point for a new category of integrated care platforms.
6.
The playbook has been contradicted. Assumptions that muscle loss is minor or that protein shakes solve the depletion problem are being contradicted by clinical evidence. Strategic resilience now requires a fundamental update to consumer health models.
$63B
The global market valuation for GLP-1 therapies in 2025.
1 in 8
North American adults have utilized GLP-1 agonists.
-5.5%
Average grocery spend drops within 6 months of starting therapy.
$238B
The total market opportunity and impact projected by 2034.
The death of the default craving
The entire food industry is preparing for a consumer who eats less. That is the wrong consumer to prepare for.
GLP-1 receptor agonists do not simply tell the stomach to feel full. They operate on the mesolimbic dopamine system, the same neural circuit that governs reward, motivation, and craving. The drug does not suppress hunger in isolation. It quiets the loop that makes food, alcohol, nicotine, and other habituated behaviors feel worth pursuing. Weight loss is one downstream effect of that neurological intervention. It is not the mechanism. Companies building strategy around the appetite suppression frame are solving for the symptom while the cause rewires the consumer underneath them.
The scale of what is already in market makes this a present-tense problem, not a future-state one. One in eight North American adults has already used a GLP-1 agonist. The non-diabetic user base grew 700% between 2019 and 2023. Grocery spending among GLP-1 users dropped more than 5% within six months of starting treatment. Fast food and limited-service restaurant spending fell more than 8%. Purchases of calorie-dense processed items fell 11%. Every industry built on habitual consumption is already operating inside this disruption. Most are still treating it as a dietary trend.
Gareth Armanious, PhD
Technical Director | PreScouter
The instinct is to look at GLP-1 through a food and beverage lens because that is where the volume signal is clearest. But the dopamine pathway does not distinguish between a bag of chips and a cigarette. The industries that understand they are looking at a reward disruption event, not a satiety trend, are the ones that will position early enough to matter.
“The data confirms this is not a dietary shift. In controlled trials for alcohol use disorder, semaglutide drove a 41% reduction in consumption and a 23% drop in cravings, with 64% of participants reaching zero heavy drinking days within eight weeks. Similarly, exenatide nearly doubled smoking abstinence rates, an effect that persisted regardless of BMI. The drug is not helping consumers make better choices. It is changing what they want.”
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
There is more of a tolerance vs. appetite decision when it comes to eating. People will pull back on heavier, greasier, spicier foods if it induces nausea, acid reflux, or general GI discomfort. Impulse snacking subsides, food noise is lowered, and people become more selective, leaning toward protein-forward, simple meals that make them feel their best physically.
Solving a problem the drug already solved
The food and supplement industry’s response to GLP-1 has been fast, visible, and largely misdirected. Nestlé launched Vital Pursuit, a high-protein, portion-controlled meal line positioned for GLP-1 users. Herbalife introduced a GLP-1 Nutrition Companion built around protein shakes and fiber. Whole Health followed with a dietitian-formulated nutrient powder. The category is moving. The underlying logic is not holding up.
Every one of these products is built on the same assumption: that GLP-1 users need help feeling full. They do not. Appetite suppression is the one thing the drug handles without assistance. A study of 22,712 U.S. households found that GLP-1 users reduced grocery spending by 5.5% within six months of starting treatment. These are not consumers struggling to eat less. They are already eating significantly less, and the question that matters is whether what they do eat contains enough nutritional density to prevent physiological decline. Formulating for satiety in this population is solving a problem the prescription already solved.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The products that will matter in three years are being built on the biology of this specific population, not on what worked for diet culture in 2015. In CPG product development, the instinct is always to lead with the benefit the consumer can feel immediately. Satiety is tangible. Bone density is not. The problem is that GLP-1 users are not a standard calorie-restriction cohort. Their nutritional exposure window is compressed in ways that legacy formulation playbooks were never designed to address.
The real problem is the risk of inadequate nutrient intake. When caloric intake drops sharply and stays low, the body’s access to micronutrients drops with it. Calcium, vitamin D, magnesium, collagen, and zinc each play distinct and non-substitutable roles in maintaining muscle integrity, bone density, immune function, and metabolic health. None of them are adequately addressed by a protein shake. Tirzepatide trials show that roughly 25% of weight lost on GLP-1 therapy is lean mass, not fat, and the consequences compound with age. For adults over 60, every pound lost carries an estimated 25% muscle and bone component, in a population that already starts from a compromised baseline. The brands leading the current product wave are fortifying against the wrong deficit.
- Research Publication
Get the complete GLP-1 strategic disruption analysis
A deep-dive into how GLP-1 drugs are changing consumer cravings, category demand, and long-term market strategy. The brief examines exposed industries, nutrient gaps, and the platform opportunities emerging around integrated care.
The invisible skeletal deficit
Muscle loss from GLP-1 therapy has entered the mainstream conversation. Fitness brands are responding. Protein is being repositioned. Noom built a Muscle Defense protocol. Equinox launched a GLP-1-specific strength program. The industry has identified lean mass preservation as the primary physiological challenge and organized around it. That response is correct and insufficient, because it is addressing the visible risk while the more serious one accumulates undetected.
Bone loss does not show up in the mirror. It does not produce fatigue or weakness that a user can attribute to their medication. It does not appear in any consumer-facing metric. It shows up years later as a fracture, a density scan, a diagnosis. A 2024 randomized study tracked bone mineral density at the hip, spine, and forearm across four intervention groups over 52 weeks. The group receiving liraglutide without exercise showed significant BMD reductions at both the hip and lumbar spine by the end of the study. The exercise-plus-liraglutide group showed substantially less loss, which confirms the mechanism and points directly at the intervention.
Expert Commentary
Thuy Ngo, PhD
Project Architect | PreScouter
The bone density data is not ambiguous. What is ambiguous is whether the industry will move on it. The clinical signal is already there. The product response is not. That is a window, and windows in consumer health tend to close fast once the first brand names the category correctly. Only 17% of current GLP-1 users are in behavioral therapy, and 39% are not enrolled in any whole-person health program at all. The population most at risk is the one least likely to be receiving the protocol that mitigates it.
The nutritional gap that drives bone loss is also more complex than the muscle conversation acknowledges. Protein matters for lean mass. Bone mass requires an entirely different stack: calcium, vitamin D, magnesium, collagen, and zinc, each playing distinct and non-interchangeable roles. A GLP-1 user on a high-protein shake who is not supplementing this stack is preserving muscle while their skeletal system quietly deteriorates. The two risks are related but not solved by the same intervention, and the market has not yet built a product that addresses both with the specificity this population requires. That gap is the opportunity, and it is sitting open right now.
Download the GLP-1 Strategic Report
Get the complete analysis, including detailed category risk profiles, potential nutrient gaps data, and the full expert panel commentary.
Rituals without rewards: alcohol & tobacco
The category-level reading of GLP-1 inside most beverage alcohol strategy decks is that the impact is real but manageable, a modest volume headwind concentrated among health-conscious consumers who were probably drinking less anyway. That conclusion misses what the mechanism is actually doing.
The reduction in alcohol consumption among GLP-1 users is not a downstream effect of eating less, feeling healthier, or making better lifestyle choices. It is a direct consequence of the same neurological rewiring that reduces food cravings. GLP-1 receptors are expressed in the brain’s reward circuitry. When the drug activates those receptors, it dampens the dopamine response to reward stimuli broadly, food, alcohol, and nicotine alike.
The tobacco picture is structurally identical and strategically worse. A 2025 randomized trial found that exenatide raised smoking abstinence rates from 26.8% to 46.3% when combined with standard nicotine patch therapy, with the effect holding regardless of BMI. The mechanism here is the same: GLP-1 receptor activation in the mesolimbic system reduces the reinforcing value of nicotine.
Expert Commentary
Jorge Hurtado, PhD
Senior Analyst | PreScouter
GLP-1 is a faster and more persistent version of that shift, because the mechanism is not cultural. It is chemical. The historical precedent that matters here is not in pharma. It is in how the alcohol industry responded to the drunk driving campaigns of the 1980s, which created an entirely new non-alcoholic occasion. The brands that moved early built category leadership that held for decades. The ones that waited defended volume until they couldn’t.
The alcohol industry at least retains the social occasion, the glass, the ritual, the moment, and can credibly pivot toward functional non-alcoholic beverages that capture it. Tobacco has no equivalent. The hand-to-mouth ritual can be addressed with nicotine-free inhalers, but the craving mechanism that makes tobacco sticky is precisely the mechanism the drug dampens. No validated GLP-1-compatible tobacco product exists today. There is only earlier or later portfolio diversification.
The unclaimed strategic platform
The conversation about GLP-1 opportunity has organized almost entirely around products. Which supplement wins the micronutrient gap. Which beverage brand captures the alcohol occasion. Which fitness platform builds the muscle preservation protocol. Those are real opportunities and they are being pursued. What is not being pursued, by anyone at meaningful scale, is the position that sits above all of them: the integrated support relationship with the GLP-1 user across the full arc of their treatment journey.
These numbers do not describe a population with a side effect problem. They describe a population undergoing a significant neurological transition, with measurable psychological consequences, receiving almost none of the support infrastructure that transition requires. The drug is doing something real to how these people experience reward, motivation, craving, and mood. The care model has not caught up.
The Wisp-Nourish partnership is the clearest early signal of what the integrated model looks like in practice. Wisp, a women’s health telehealth provider, partnered with Nourish to offer nutrition counseling to GLP-1 patients as part of their weight management program, accessible through insurance or discounted self-pay. It addresses nutrient intake, supports behavioral change through personalized guidance, and extends the care relationship beyond the prescription.
It is not comprehensive, but it is the right shape. The brands that build this model at scale, combining telehealth, nutrition counseling, fitness programming, behavioral health support, and pharmacological monitoring into a single user relationship, will own something no supplement SKU or protein shake can compete with. That is not a product. That is a platform. And it does not yet exist.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The brands that see it as a product adjacency will build supplements. The brands that see it as a platform opportunity will build something that compounds. What the data tells you is that GLP-1 users are not passive. They are actively seeking support that the current market is not providing. Seventy-five percent raising their hand for behavioral help is not a niche signal. That is a category waiting to be built.
Five questions that apply here, and to every decarbonization decision
01
Are you solving for the mechanism or the symptom?
In GLP-1, companies building for appetite suppression are solving for the symptom. The mechanism is reward disruption, and it extends to alcohol, tobacco, and every other habituated behavior. Every large disruption has an equivalent distinction between what is visibly happening and what is actually driving it. The strategy built on the visible thing will be outpaced by the one built on the mechanism.
02
What does your portfolio look like if the craving disappears?
GLP-1 does not reduce consumption by making people more disciplined. It reduces the neurological reinforcement that made the behavior feel worth repeating. Any business that depends on habitual repurchase should stress-test its model against a consumer who no longer experiences the craving that drove the habit. If the value proposition only works when the want is intact, the brand is more exposed than the revenue line currently suggests.
03
Are you moving on the invisible risk or waiting for the visible one?
Bone loss is not showing up in consumer complaints or product returns. It is showing up in clinical data that most product teams have not read. The visible risk in GLP-1 is lean mass loss, and the market is already responding. The invisible risk is bone density decline, and the market is not. In every disruption, the invisible risk is where the first-mover advantage is largest and the window is longest, because most competitors are still watching the visible one.
04
Is the gap between what your customer needs and what you offer a problem or a position?
Seventy-five percent of GLP-1 users want behavioral support. Seventeen percent are receiving it. That 58-point gap is not a failure of awareness. It is a market that has not yet been built. In any disruption, the largest unmet need is not always obvious to the incumbents closest to it. The question is whether you see the gap as someone else’s problem to solve or as the highest-value position available to you.
05
Does your response timeline survive the actual pace of adoption?
The GLP-1 user base grew 700% in four years among non-diabetic users alone. Oral formulations are positioned to lower the primary adoption barrier. The planning horizon most companies are using for their GLP-1 response is not calibrated to that adoption curve. Test every strategic response against a scenario where penetration doubles in the next 24 months. If the response only works given more time, it is already late.
Contributing Experts
Gareth Armanious, PhD
Technical Director | PreScouter
Gareth is the Technical Director of Food & Beverage at PreScouter, where he’s driven strategy and scientific research for Fortune 500s since 2015. He built and leads the F&B team, architecting systems and services that shaped company-wide execution. His expertise spans food, beverage, and life sciences, rooted in a research background in membrane protein biochemistry and prior coordination roles in oncology research.
Victoria Yeung, MBS
Senior Project Architect | PreScouter
Victoria is one of PreScouter’s Project Architects specializing in the Food & Beverage industry. She holds a BS and MBS in Food Science from Rutgers University, where her research focused on identification of photosensitizers for the inactivation of foodborne pathogens. Prior to joining PreScouter, Victoria worked as a scientist at a Fortune 500 consumer packaged goods company, specializing in flavor technology and driving innovations across R&D.
Thuy Ngo, PhD
Project Architect | PreScouter
Thuy earned her PhD degree in Advanced Fusion Technology from Konkuk University, and her Advanced Master in Intellectual Property Law and Knowledge Management from Maastricht University. Before joining PreScouter, she worked as a Research Professor in the field of Structural Biology at Konkuk University where she researched antibacterial drugs and industrial enzymes by leveraging protein tertiary structure. At PreScouter, she specializes in and manages service delivery for clients in the Food&Bev and Life Sciences sectors. She is currently based in Ho Chi Minh City, Vietnam.
Jorge Hurtado, PhD
Senior Analyst | PreScouter
Jorge works as a Senior Analyst at PreScouter. His expertise spans a broad spectrum of technological fields. He holds a Master’s degree in Conservation and Development, a Ph.D. in Biology from the University of Florida and Syracuse University, respectively, and a diploma in Green Economy from Toronto Metropolitan University.
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
Carrie is a registered dietitian with over 13 years of experience, known for blending evidence-based nutrition with practical, culinary-focused guidance. Her work spans recipe development and brand collaborations, as well as nutrition counseling, particularly with women navigating perimenopause, menopause, and GLP-1–related weight management. Carrie specializes in helping people build confidence in home cooking and using whole foods in realistic ways that account for time, budget, and convenience constraints.